Literature DB >> 32059590

In Vitro Antimicrobial Activity of Various Cefoperazone/Sulbactam Products.

Ming-Jen Sheu1,2, Chi-Chung Chen3,4, Ying-Chen Lu3, Bo-An Su5, Chun-Cheng Zhang5, Shu-Shen Wang5, Yin-Ching Chuang2,4, Hung-Jen Tang5, Chih-Cheng Lai6.   

Abstract

: This study aims to assess the in vitro activity of different samples of cefoperazone/sulbactam (CFP/SUL) against multidrug-resistant organisms (MDROs). Clinical isolates of extended-spectrum β-lactamase (ESBL)-Escherichia coli, ESBL-Klebsiella pneumoniae, carbapenem-resistant Acinetobacter baumannii (CR-AB), and carbapenem-resistant Pseudomonas aeruginosa (CR-PA) were collected. The minimum inhibitory concentration (MIC) and time-killing methods were used to assess and compare the in vitro activities of different samples of cefoperazone/sulbactam (CFP/SUL) against these MDROs. For ESBL-E. coli, ESBL-K. pneumoniae, and CR-PA, product C had smaller variations than product A and B (p < 0.05). For CR-AB, product B had the largest variation compared to the other two products (p < 0.05). In the time-killing studies, significant differences among the products when used at 16/16 µg/mL were noted for ESBL-E. coli, ESBL-K. pneumoniae, and CR-AB isolates. In conclusion, this study demonstrated the significantly different activity of different products of CFP/SUL against MDROs.

Entities:  

Keywords:  antimicrobial activity; cefoperazone/sulbactam; multidrug-resistant organism

Year:  2020        PMID: 32059590     DOI: 10.3390/antibiotics9020077

Source DB:  PubMed          Journal:  Antibiotics (Basel)        ISSN: 2079-6382


  5 in total

1.  Optimal Dose of Cefoperazone-Sulbactam for Acute Bacterial Infection in Patients with Chronic Kidney Disease.

Authors:  Chien-Ming Chao; Chih-Cheng Lai; Chen-Hsiang Lee; Hung-Jen Tang
Journal:  Antibiotics (Basel)       Date:  2022-04-30

2.  Clinical Outcomes and Adverse Effects in Septic Patients with Impaired Renal Function Who Received Different Dosages of Cefoperazone-Sulbactam.

Authors:  Chien-Hsiang Tai; Hung-Jen Tang; Chen-Hsiang Lee
Journal:  Antibiotics (Basel)       Date:  2022-03-29

3.  In Vitro Activity of Various Sulbactam Compounds and Piperacillin/Tazobactam against Clinical Isolates of Different Gram-Negative Bacteria.

Authors:  Shunian Xiao; Chuyue Zhuo; Chao Zhuo
Journal:  Comput Math Methods Med       Date:  2021-11-25       Impact factor: 2.238

4.  Model-Informed Drug Development of New Cefoperazone Sodium and Sulbactam Sodium Combination (3:1): Pharmacokinetic/Pharmacodynamic Analysis and Antibacterial Efficacy Against Enterobacteriaceae.

Authors:  Xi-Wei Ji; Xiao Zhu; Yun Li; Feng Xue; Isabelle Hui San Kuan; Qing-Feng He; Xiang-Rui Meng; Xiao-Qiang Xiang; Yi-Min Cui; Bo Zheng
Journal:  Front Pharmacol       Date:  2022-07-18       Impact factor: 5.988

5.  Clinical Efficacy of Cefoperazone-Sulbactam versus Piperacillin-Tazobactam in the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia.

Authors:  Chia-Hung Chen; Chih-Yen Tu; Wei-Chih Chen; Li-Kuo Kuo; Yao-Tung Wang; Pin-Kuei Fu; Shih-Chi Ku; Wen-Feng Fang; Chin-Ming Chen; Chih-Cheng Lai
Journal:  Infect Drug Resist       Date:  2021-06-16       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.